Cocrystal Pharma FY21 EPS $(0.16) Up From $(0.17) YoY
Cocrystal Pharma (NASDAQ:COCP) reported quarterly losses of $(0.16) per share. This is a 5.88 percent increase over losses of $(0.17) per share from the same period last year.
COCP: Cocrystal Pharma has secured funding to enter three clinical trials and fund planned operations through 2023
By Thomas Kerr, CFA
NASDAQ:COCP
READ THE FULL COCP RESEARCH REPORT
Cocrystal Pharma To Develop Additional Two Antiviral Drug Candidates For COVID-19
Cocrystal Pharma Inc (NASDAQ: COCP) has selected two investigational novel antiviral drug candidates for further development as oral treatm
Stocks That Hit 52-Week Lows On Friday
Before 10 am on Friday, 110 companies set new 52-week lows.
Cocrystal’s COVID-19 Antiviral Candidate Shows Potency Against Omicron Variant
Cocrystal Pharma Inc's (NASDAQ: COCP) COVID-19 antiviral candidate has shown antiviral potency against the omicron variant in vitro studies.
Cocrystal Pharma Files To Start Human Trial For Protease Inhibitor In COVID-19
Cocrystal Pharma Inc (NASDAQ: COCP) has submitted a pre-Investigational New Drug (IND) briefing package to the FDA for its broad-spectrum protease inhibitor CDI-45205 in COVID-19.
Cocrystal Pharma Submits Pre-Investigational New Drug Briefing Package To The FDA For Clinical Development Guidance Of CDI-45205 For COVID-19 Treatment
Cocrystal Pharma, Inc. (NASDAQ:COCP) (“Cocrystal” or the “Company”) announces the submission of a pre-Investigational New Drug (IND) briefing package to the U.S. Food and Drug Administration (FDA)
Cocrystal Pharma To Present Data From Oral And Intranasal COVID-19 Therapeutics Programs At The World Antiviral Congress 2021
Cocrystal Pharma, Inc. (NASDAQ:COCP) ("Cocrystal" or the "Company"), a clinical-stage company discovering and developing novel antiviral therapeutics, announces that President and co-interim CEO